JP2010513561A - Ｉａｐのイミダゾピリジンインヒビター - Google Patents

Ｉａｐのイミダゾピリジンインヒビター Download PDF

Info

Publication number
JP2010513561A
JP2010513561A JP2009543099A JP2009543099A JP2010513561A JP 2010513561 A JP2010513561 A JP 2010513561A JP 2009543099 A JP2009543099 A JP 2009543099A JP 2009543099 A JP2009543099 A JP 2009543099A JP 2010513561 A JP2010513561 A JP 2010513561A
Authority
JP
Japan
Prior art keywords
alkyl
heterocycle
carbocycle
optionally substituted
amino
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
JP2009543099A
Other languages
English (en)
Japanese (ja)
Other versions
JP2010513561A5 (cg-RX-API-DMAC7.html
Inventor
マイケル エフ．ティ． コーラー，
Original Assignee
ジェネンテック， インコーポレイテッド
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by ジェネンテック， インコーポレイテッド filed Critical ジェネンテック， インコーポレイテッド
Publication of JP2010513561A publication Critical patent/JP2010513561A/ja
Publication of JP2010513561A5 publication Critical patent/JP2010513561A5/ja
Ceased legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/437—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a five-membered ring having nitrogen as a ring hetero atom, e.g. indolizine, beta-carboline
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K5/00—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
    • C07K5/04—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing only normal peptide links
    • C07K5/06—Dipeptides
    • C07K5/06008—Dipeptides with the first amino acid being neutral
    • C07K5/06017—Dipeptides with the first amino acid being neutral and aliphatic
    • C07K5/06026—Dipeptides with the first amino acid being neutral and aliphatic the side chain containing 0 or 1 carbon atom, i.e. Gly or Ala

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Hematology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Oncology (AREA)
  • Epidemiology (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
JP2009543099A 2006-12-19 2007-12-14 Ｉａｐのイミダゾピリジンインヒビター Ceased JP2010513561A (ja)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US87082106P 2006-12-19 2006-12-19
PCT/US2007/087532 WO2008079735A1 (en) 2006-12-19 2007-12-14 Imidazopyridine inhibitors of iap

Publications (2)

Publication Number Publication Date
JP2010513561A true JP2010513561A (ja) 2010-04-30
JP2010513561A5 JP2010513561A5 (cg-RX-API-DMAC7.html) 2011-02-03

Family

ID=39361343

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2009543099A Ceased JP2010513561A (ja) 2006-12-19 2007-12-14 Ｉａｐのイミダゾピリジンインヒビター

Country Status (12)

Country Link
US (2) US8063218B2 (cg-RX-API-DMAC7.html)
EP (1) EP2125809A1 (cg-RX-API-DMAC7.html)
JP (1) JP2010513561A (cg-RX-API-DMAC7.html)
KR (1) KR20090094461A (cg-RX-API-DMAC7.html)
CN (1) CN101605786A (cg-RX-API-DMAC7.html)
AU (1) AU2007337104A1 (cg-RX-API-DMAC7.html)
BR (1) BRPI0719481A2 (cg-RX-API-DMAC7.html)
CA (1) CA2671607A1 (cg-RX-API-DMAC7.html)
IL (1) IL198927A0 (cg-RX-API-DMAC7.html)
NZ (1) NZ577150A (cg-RX-API-DMAC7.html)
RU (1) RU2466131C2 (cg-RX-API-DMAC7.html)
WO (1) WO2008079735A1 (cg-RX-API-DMAC7.html)

Cited By (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2021502397A (ja) * 2017-11-13 2021-01-28 チア タイ ティエンチン ファーマシューティカル グループ カンパニー リミテッドChia Tai Tianqing Pharmaceutical Group Co., Ltd. Ｉａｐ阻害剤として有用なｓｍａｃ模倣物及びその用途
JP2022531794A (ja) * 2019-05-10 2022-07-11 チア タイ ティエンチン ファーマシューティカル グループ カンパニー リミテッド Ｉａｐ阻害剤としてのｓｍａｃ模倣物の結晶及びその製造方法

Families Citing this family (28)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1773766B1 (en) 2004-07-15 2014-04-02 Tetralogic Pharmaceuticals Corporation Iap binding compounds
EA019420B1 (ru) 2004-12-20 2014-03-31 Дженентех, Инк. Пирролидиновые ингибиторы иап (ингибиторов апоптоза)
AU2006216450C1 (en) 2005-02-25 2013-01-10 Medivir Ab Dimeric IAP inhibitors
CA2607940C (en) 2005-05-18 2009-12-15 Aegera Therapeutics Inc. Bir domain binding compounds
US20100256046A1 (en) * 2009-04-03 2010-10-07 Tetralogic Pharmaceuticals Corporation Treatment of proliferative disorders
WO2007048224A1 (en) 2005-10-25 2007-05-03 Aegera Therapeutics Inc. Iap bir domain binding compounds
TWI504597B (zh) 2006-03-16 2015-10-21 Pharmascience Inc 結合於細胞凋亡抑制蛋白（ｉａｐ）之桿狀病毒ｉａｐ重複序列（ｂｉｒ）區域之化合物
SG171682A1 (en) 2006-05-16 2011-06-29 Aegera Therapeutics Inc Iap bir domain binding compounds
EP2049524A2 (en) * 2006-07-24 2009-04-22 Tetralogic Pharmaceuticals Corporation Iap inhibitors
US20100056495A1 (en) * 2006-07-24 2010-03-04 Tetralogic Pharmaceuticals Corporation Dimeric iap inhibitors
WO2008014240A2 (en) * 2006-07-24 2008-01-31 Tetralogic Pharmaceuticals Corporation Dimeric iap inhibitors
US20100143499A1 (en) * 2006-07-24 2010-06-10 Tetralogic Pharmaceuticals Corporation Dimeric iap inhibitors
US20100144650A1 (en) * 2006-07-24 2010-06-10 Tetralogic Pharmaceuticals Corporation Dimeric iap inhibitors
AU2007276760B2 (en) * 2006-07-24 2012-01-19 Tetralogic Pharmaceuticals Corporation Dimeric IAP antagonists
EP2148858A4 (en) * 2007-04-30 2011-01-26 Genentech Inc IPA INHIBITORS
EP2156189A1 (en) * 2007-05-07 2010-02-24 Tetralogic Pharmaceuticals Corp. Tnf gene expression as a biomarker of sensitivity to antagonists of inhibitor of apoptosis proteins
CA2711606A1 (en) * 2008-01-11 2009-07-16 Genentech, Inc. Inhibitors of iap
EP2318395A4 (en) * 2008-08-02 2011-10-26 Genentech Inc IPA INHIBITORS
AU2009282978A1 (en) * 2008-08-16 2010-02-25 Genentech, Inc. Azaindole inhibitors of IAP
US8283372B2 (en) 2009-07-02 2012-10-09 Tetralogic Pharmaceuticals Corp. 2-(1H-indol-3-ylmethyl)-pyrrolidine dimer as a SMAC mimetic
WO2011016576A1 (en) 2009-08-04 2011-02-10 Takeda Pharmaceutical Company Limited Alanine derivatives as inhibitors of apoptosis proteins
NZ600608A (en) 2009-12-18 2015-01-30 Idenix Pharmaceuticals Inc 5,5-fused arylene or heteroarylene hepatitis c virus inhibitors
EP3263583A1 (en) 2010-02-12 2018-01-03 Pharmascience Inc. Iap bir domain binding compounds
WO2012030160A2 (en) * 2010-08-31 2012-03-08 Hanmi Holdings Co., Ltd. Quinoline or quinazoline derivatives with apoptosis inducing activity on cells
KR20140011773A (ko) * 2012-07-19 2014-01-29 한미약품 주식회사 이중 저해 활성을 갖는 헤테로고리 유도체
JP7515175B2 (ja) 2018-07-31 2024-07-12 ファイメクス株式会社 複素環化合物
WO2020177765A1 (zh) * 2019-03-07 2020-09-10 正大天晴药业集团股份有限公司 Iap抑制剂与免疫检查点抑制剂的组合
US20220402935A1 (en) 2019-07-31 2022-12-22 Fimecs, Inc. Heterocyclic compound

Citations (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2005097791A1 (en) * 2004-04-07 2005-10-20 Novartis Ag Inhibitors of iap
JP2006501181A (ja) * 2002-07-02 2006-01-12 ノバルティス アクチエンゲゼルシャフト Ｓｍａｃタンパク質のアポトーシスタンパク質阻害物質（ｉａｐ）との結合に対するペプチド阻害剤
WO2006069063A1 (en) * 2004-12-20 2006-06-29 Genentech, Inc. Pyrrolidine inhibitors of iap
WO2007106192A2 (en) * 2005-12-19 2007-09-20 Genentech, Inc. Inhibitors of iap
WO2008016893A1 (en) * 2006-08-02 2008-02-07 Novartis Ag Smac peptidomimetics useful as iap inhibitors
WO2008045905A1 (en) * 2006-10-12 2008-04-17 Novartis Ag Pyrrolydine derivatives as iap inhibitors

Family Cites Families (33)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
SE430062B (sv) * 1977-03-04 1983-10-17 Pharmacia Fine Chemicals Ab Kopplings- eller tioleringsreagens
DE2714880A1 (de) * 1977-04-02 1978-10-26 Hoechst Ag Cephemderivate und verfahren zu ihrer herstellung
FR2575753B1 (fr) * 1985-01-07 1987-02-20 Adir Nouveaux derives peptidiques a structure polycyclique azotee, leur procede de preparation et les compositions pharmaceutiques qui les contiennent
DE3685626T2 (de) * 1985-09-26 1993-01-28 Beckmann Research Inst Of The Sequenzierung von peptiden.
US4935494A (en) * 1988-11-15 1990-06-19 City Of Hope C-terminal peptide and protein sequencing
DK167813B1 (da) * 1989-12-07 1993-12-20 Carlbiotech Ltd As Pentapeptidderivat, farmaceutisk acceptable salte heraf, fremgangsmaade til fremstilling deraf og farmaceutisk praeparat indeholdende et saadant derivat
WO1992001938A1 (en) 1990-07-20 1992-02-06 City Of Hope Derivatization of c-terminal proline
DE69329503T2 (de) 1992-11-13 2001-05-03 Idec Pharma Corp Therapeutische Verwendung von chimerischen und markierten Antikörpern, die gegen ein Differenzierung-Antigen gerichtet sind, dessen Expression auf menschliche B Lymphozyt beschränkt ist, für die Behandlung von B-Zell-Lymphoma
US5559209A (en) * 1993-02-18 1996-09-24 The General Hospital Corporation Regulator regions of G proteins
US6335155B1 (en) 1998-06-26 2002-01-01 Sunesis Pharmaceuticals, Inc. Methods for rapidly identifying small organic molecule ligands for binding to biological target molecules
US6472172B1 (en) * 1998-07-31 2002-10-29 Schering Aktiengesellschaft DNA encoding a novel human inhibitor-of-apoptosis protein
JP2002533726A (ja) 1998-12-28 2002-10-08 サネシス ファーマシューティカルス インコーポレイテッド 結合のための小有機分子リガンドの同定
US6608026B1 (en) * 2000-08-23 2003-08-19 Board Of Regents, The University Of Texas System Apoptotic compounds
WO2002016418A2 (en) 2000-08-24 2002-02-28 Thomas Jefferson University An iap binding peptide or polypeptide and methods of using the same
WO2004007529A2 (en) 2002-07-15 2004-01-22 The Trustees Of Princeton University Iap binding compounds
US6992063B2 (en) * 2000-09-29 2006-01-31 The Trustees Of Princeton University Compositions and method for regulating apoptosis
WO2002026775A2 (en) 2000-09-29 2002-04-04 Trustees Of Princeton University Compositions and methods for regulating apoptosis
WO2002030959A2 (en) 2000-10-13 2002-04-18 Abbott Laboratories Peptides derived from smac (diablo) and methods of use therefor
AU2002253908A1 (en) 2001-02-08 2003-02-17 Thomas Jefferson University A conserved xiap-interaction motif in caspase-9 and smac/diablo for mediating apoptosis
EP1421204A4 (en) 2001-05-31 2004-12-15 Univ Princeton IAP-BINDING PEPTIDES AND ASSAYS FOR IDENTIFYING IAP-BINDING COMPOUNDS
WO2003040172A2 (en) * 2001-11-09 2003-05-15 Aegera Therapeutics, Inc. Methods and reagents for peptide-bir interaction screens
EP1495124A2 (en) 2002-04-17 2005-01-12 Deutsches Krebsforschungszentrum Stiftung des öffentlichen Rechts Smac-peptides as therapeutics against cancer and autoimmune diseases
WO2004017991A1 (en) 2002-08-13 2004-03-04 Cell Center Cologne Gmbh Use of iap for the diagnosis and of iap-inhibitors for the treatment of hodgkin’s lymphomas
US20040171554A1 (en) * 2003-02-07 2004-09-02 Genentech, Inc. Compositions and methods for enhancing apoptosis
WO2004072641A1 (en) 2003-02-07 2004-08-26 Genentech, Inc. Compositions and methods for enhancing apoptosis
IL156263A0 (en) 2003-06-02 2004-01-04 Hadasit Med Res Service Livin-derived peptides, compositions and uses thereof
SE0301904D0 (sv) * 2003-06-26 2003-06-26 Astrazeneca Ab Novel imidazopyridine compound II with therapeutic effect
CA2543897A1 (en) * 2003-11-13 2005-06-02 Genentech, Inc. Compositions and methods for screening pro-apoptotic compounds
JP4674231B2 (ja) * 2004-03-01 2011-04-20 ボード・オブ・リージエンツ，ザ・ユニバーシテイ・オブ・テキサス・システム ２量体小分子アポトーシス増強剤
MXPA06014969A (es) * 2004-07-02 2007-02-08 Genentech Inc Inhibidores de iap.
EP1773766B1 (en) 2004-07-15 2014-04-02 Tetralogic Pharmaceuticals Corporation Iap binding compounds
CN1808446A (zh) * 2005-01-22 2006-07-26 鸿富锦精密工业（深圳）有限公司 高速电路中耦合传输线等效模型的撷取方法
AU2006216450C1 (en) 2005-02-25 2013-01-10 Medivir Ab Dimeric IAP inhibitors

Patent Citations (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2006501181A (ja) * 2002-07-02 2006-01-12 ノバルティス アクチエンゲゼルシャフト Ｓｍａｃタンパク質のアポトーシスタンパク質阻害物質（ｉａｐ）との結合に対するペプチド阻害剤
WO2005097791A1 (en) * 2004-04-07 2005-10-20 Novartis Ag Inhibitors of iap
WO2006069063A1 (en) * 2004-12-20 2006-06-29 Genentech, Inc. Pyrrolidine inhibitors of iap
WO2007106192A2 (en) * 2005-12-19 2007-09-20 Genentech, Inc. Inhibitors of iap
WO2008016893A1 (en) * 2006-08-02 2008-02-07 Novartis Ag Smac peptidomimetics useful as iap inhibitors
WO2008045905A1 (en) * 2006-10-12 2008-04-17 Novartis Ag Pyrrolydine derivatives as iap inhibitors

Non-Patent Citations (2)

* Cited by examiner, † Cited by third party
Title
JPN6012032836; Ｅｕｒ．　Ｊ．　Ｍｅｄ．　Ｃｈｅｍ． Ｖｏｌ．３５, 2000, ｐ．２５７-６６ *
JPN6012032836; Ｊｏｙｅａｕ　Ｒ　ｅｔ　ａｌ: Ｅｕｒ　Ｊ　Ｍｅｄ　Ｃｈｅｍ Ｖｏｌ．３５, 2000, ｐ．２５７-６６ *

Cited By (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2021502397A (ja) * 2017-11-13 2021-01-28 チア タイ ティエンチン ファーマシューティカル グループ カンパニー リミテッドChia Tai Tianqing Pharmaceutical Group Co., Ltd. Ｉａｐ阻害剤として有用なｓｍａｃ模倣物及びその用途
JP7257397B2 (ja) 2017-11-13 2023-04-13 チア タイ ティエンチン ファーマシューティカル グループ カンパニー リミテッド Ｉａｐ阻害剤として有用なｓｍａｃ模倣物及びその用途
JP2022531794A (ja) * 2019-05-10 2022-07-11 チア タイ ティエンチン ファーマシューティカル グループ カンパニー リミテッド Ｉａｐ阻害剤としてのｓｍａｃ模倣物の結晶及びその製造方法
JP7587526B2 (ja) 2019-05-10 2024-11-20 チア タイ ティエンチン ファーマシューティカル グループ カンパニー リミテッド Ｉａｐ阻害剤としてのｓｍａｃ模倣物の結晶及びその製造方法

Also Published As

Publication number Publication date
KR20090094461A (ko) 2009-09-07
AU2007337104A1 (en) 2008-07-03
US20120015974A1 (en) 2012-01-19
BRPI0719481A2 (pt) 2014-02-11
NZ577150A (en) 2012-04-27
IL198927A0 (en) 2010-02-17
CA2671607A1 (en) 2008-07-03
EP2125809A1 (en) 2009-12-02
WO2008079735A1 (en) 2008-07-03
CN101605786A (zh) 2009-12-16
RU2466131C2 (ru) 2012-11-10
US20100130539A1 (en) 2010-05-27
RU2009127800A (ru) 2011-01-27
US8063218B2 (en) 2011-11-22

Similar Documents

Publication Publication Date Title
JP5155184B2 (ja) Ｉａｐのインヒビター
RU2466131C2 (ru) Имидазопиридиновые ингибиторы iap
JP5368428B2 (ja) Ｉａｐのインヒビター
JP4850175B2 (ja) Ｉａｐのインヒビター
JP5007235B2 (ja) Ｉａｐのピロリジンインヒビター
JP5122275B2 (ja) Ｉａｐのアザビシクロ−オクタンインヒビター
US20110218211A1 (en) Azaindole inhibitors of iap
EP2240506B1 (en) Inhibitors of iap

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20101208

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20101208

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20121120

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20130220

A045 Written measure of dismissal of application [lapsed due to lack of payment]

Free format text: JAPANESE INTERMEDIATE CODE: A045

Effective date: 20140401